Evidence map›Paper›PMID 21103956›Full record

ArticleJournal of gastrointestinal cancer2011

Comparison of two diverse populations, British Columbia, Canada, and Ardabil, Iran, indicates several variables associated with gastric and esophageal cancer survival.

Morteza Bashash, Parvin Yavari, T Greg Hislop, Amil Shah, Alireza Sadjadi, Masoud Babaei, Nhu Le, Angela Brooks-Wilson, Reza Malekzadeh, Chris Bajdik

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of gastrointestinal cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Survival of gastric cancer patients in Iran: a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2023
    Review
  3. Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review.Clinical and experimental gastroenterology · 2020
    Review
  4. Article
  5. Survival rate of gastric cancer in Iran; a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2016
    Review
  6. Article
  7. Review
  8. The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience.International journal of hematology-oncology and stem cell research · 2014
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Morteza BashashCancer Control Research Program, BC Cancer Agency, Vancouver, Canada.
Parvin Yavari
T Greg Hislop
Amil Shah
Alireza Sadjadi
Masoud Babaei
Nhu Le
Angela Brooks-Wilson
Reza Malekzadeh
Chris Bajdik
University of British Columbia · CABC Cancer Agency · CATehran University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRShariati Hospital · IRSimon Fraser University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGeographic variation and temporal trends in the epidemiology of esophageal and gastric cancers vary according to both tumor morphology and organ subsite. This study compares 1-year survival of gastric and esophageal cancers between two distinct populations: British Columbia (BC), Canada, and Ardabil, Iran.

methodsData for invasive primary esophageal and gastric cancer patients were obtained from the population-based cancer registries for BC and Ardabil. The relative survival rate was calculated using WHO Statistical Information System (WHOSIS) life-tables for each country. Chi-square and Fisher's exact tests were used to compare survival differences between BC and Ardabil. T-tests, chi-square tests, and Fisher's exact test were used to compare patient characteristics and tumor factors between the populations.

resultsThe overall 1-year age-standardized relative survivals for gastric cancer were 48% and 21% in BC and Ardabil, respectively (p < 0.01). The overall 1-year age-standardized relative survival for esophageal cancer was 33% and 17% in BC and Ardabil, respectively (p < 0.05). Overall and separately for each gender, age group, tumor location, and histology, there was greater 1-year survival of the gastric cancer patients in BC compared to Ardabil. For esophageal cancer; patients under age 65, patients with tumors in the middle or upper third of esophagus, and patients with squamous cell carcinoma had significantly better survival in BC than in Ardabil.

conclusionFindings of this study point to differences in disease characteristics and patient factors, not solely differences in healthcare systems, as being responsible for the survival difference in these populations.

Indexed as

AdenocarcinomaAgedBritish ColumbiaCanadaCarcinoma, Squamous CellEsophageal NeoplasmsFemaleHumansIntramolecular OxidoreductasesIranMacrophage Migration-Inhibitory FactorsMaleNeoplasm StagingPrognosisRegistriesStomach NeoplasmsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID21103956
PMCPMC3040318
OpenAlexW2008485186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.